Protagonist Therapeutics, Inc Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Protagonist Therapeutics, Inc (PTGX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $11.07 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-11-07
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$772.00K, a 119.88% decline year-over-year.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $13.09M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$1.25M, a 117.49% decline year-over-year.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$64.33M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$59.33M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$8.26M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$299.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | -$772.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $12.32M derived: sum of 2 quarters · filed 2017-11-07 | $11.07M 10-Q · filed 2017-11-07 | -$53.25M derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-06-30 | $13.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $11.84M 10-Q · filed 2017-08-08 | -$52.48M derived: sum of 3 quarters · filed 2017-08-08 | -$48.60M derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-03-31 | -$1.25M 10-Q · filed 2017-05-10 | -$65.58M derived: sum of 2 quarters · filed 2017-05-10 | -$61.69M derived: sum of 3 quarters · filed 2017-11-07 | -$67.72M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-12-31 | -$64.33M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | -$60.44M derived: sum of 2 quarters · filed 2017-11-07 | -$66.47M derived: sum of 3 quarters · filed 2017-11-07 | -$59.33M 10-K · filed 2017-03-07 |
| 2016-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$2.15M derived: sum of 2 quarters · filed 2017-11-07 | $5.00M 10-Q · filed 2017-11-07 | -$3.09M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | -$6.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $1.11M 10-Q · filed 2017-08-08 | -$6.97M derived: sum of 3 quarters · filed 2017-08-08 | -$7.08M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $7.15M 10-Q · filed 2017-05-10 | -$938.00K derived: sum of 2 quarters · filed 2017-05-10 | -$1.05M derived: sum of 3 quarters · filed 2017-05-10 | |
| 2015-12-31 | -$8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | -$8.20M derived: sum of 2 quarters · filed 2017-03-07 | -$8.26M 10-K · filed 2017-03-07 | |
| 2015-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$179.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$66.00K 10-Q · filed 2016-09-15 | |||
| 2014-12-31 | -$299.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |